Vitamin C is easy to formulate only if the goal is to put ascorbic acid on a label. It becomes a harder formulation problem when the goal is predictable delivery, acceptable stability and evidence that the chosen delivery system changes exposure in a meaningful way. That distinction is why LipoDuo™ Vitamin C and other liposomal formats attract attention from nutraceutical R&D teams.

A 2025 scoping review by Anitra Carr identified 10 published studies comparing liposomal and non-liposomal vitamin C. Nine reported higher plasma bioavailability for the liposomal formulation, but the review also found major differences in dose, formulation and sampling duration. That is encouraging evidence for the delivery concept. It is not evidence that every product carrying the word "liposomal" will perform the same way.

The practical position for a formulation team is therefore more demanding than the marketing position. A buyer should ask what was encapsulated, how the system was characterised, how it behaves after processing and what evidence belongs to the exact formulation under consideration.

The evidence is promising, but the headline number is not the whole story

Carr's review reported that the included trials used vitamin C doses ranging from 0.15 g to 10 g and collected samples over periods from 4 to 24 hours. Those differences matter. If two products are tested at different doses, in different people and with different sampling schedules, a simple fold-change cannot be treated as a clean product-to-product ranking.

Cmax, the highest measured concentration after a dose, is useful because it shows the peak exposure observed in that study. AUC, or area under the concentration-time curve, estimates total exposure during the sampling window. Both are standard pharmacokinetic measures. Neither tells a formulator whether the vitamin remained stable for a year in a powder, survived a gummy process or retained the same particle characteristics after reconstitution.

The review also identified a thinner evidence base for cellular uptake and biological effects than for plasma exposure. That is a useful corrective. Plasma pharmacokinetics can show that delivery changed. They do not automatically prove a larger health effect. In B2B ingredient selection, those should be treated as separate questions.

Our view is that suppliers should resist turning one pharmacokinetic ratio into a universal promise. A technically serious buyer will ask for the study design before the fold-change.

Why "liposomal" does not describe one standard product

A liposome is a lipid vesicle built from phospholipids, but that basic definition leaves a lot of room for variation. Vesicle size, size distribution, lipid composition, surface charge, encapsulation efficiency, free versus encapsulated vitamin C and storage conditions can all influence how a preparation behaves.

That is why the 2025 review found substantial variation between liposomal vitamin C studies. The label describes a delivery architecture, not a fixed specification. In practical terms, two powders may both be sold as liposomal vitamin C while differing in particle distribution, residual free ascorbic acid, oxidation control or performance after rehydration.

A useful analogy is a capsule. Two products can both use a hard capsule, but that says little about fill quality, disintegration, moisture sensitivity or dose uniformity. Liposomal delivery deserves the same discipline. The carrier name should start the technical discussion, not end it.

One common belief deserves pushback: smaller is not automatically better. Reducing particle size can improve dispersion or surface area, but extreme size reduction may create other stability or loading trade-offs. A good specification is one that fits the intended product and remains consistent across batches.

What should be checked before selecting a liposomal vitamin C ingredient?

For an R&D team, the most useful conversation begins with the finished dosage form. A capsule blend, effervescent powder, sachet and ready-to-mix beverage impose different stresses. The same raw ingredient may not behave identically in all four.

A practical evaluation should cover:

·         Identity and assay of vitamin C, including how free and encapsulated fractions are measured.

·         Particle-size distribution rather than a single average value, because broad distributions can hide unstable or inconsistent fractions.

·         Encapsulation efficiency and the analytical method used to calculate it.

·         Oxidative and storage stability under the temperature and humidity conditions relevant to the finished product.

·         Behaviour after reconstitution, especially if the ingredient is intended for powders or beverages.

·         Batch-to-batch controls and acceptance ranges for critical physical parameters.

·         Compatibility with flavours, minerals, sweeteners, acids and processing steps used in the final formulation.

This checklist is more useful than asking whether a supplier has "nano" technology. Nano-scale terminology can describe size, but it does not replace evidence on quality or process fit.

A formulation can fail after good pharmacokinetics

A frequent blind spot in nutraceutical development is to treat an absorption study as the final quality test. A study may show higher exposure for a prototype while the commercial powder later faces agglomeration, moisture pickup or oxidation. The scientific claim and the manufacturing reality must meet in the same specification.

For vitamin C, oxidation is particularly relevant because ascorbic acid is chemically sensitive. The delivery matrix, packaging, oxygen exposure and water activity can all become part of the product story. A formulation designed for a sachet sold in humid climates may need a different risk assessment from one used in a sealed capsule bottle.

This is also where lyophilisation becomes relevant to LipoDuo Technology. Samarth Biorigins describes LipoDuo as combining liposomal encapsulation with lyophilisation, or freeze-drying, to stabilise the system as a bulk powder. That is a brand-platform claim, and finished-product teams should still verify the parameters that matter to their own process.

The stronger commercial question is not "Does liposomal vitamin C work?" It is "Does this specific liposomal ingredient retain the properties we need from incoming raw material through end-of-shelf-life testing?"

Reading a bioavailability dossier without getting distracted by one ratio

When a supplier presents human data, start with the population, comparator and dose. Healthy volunteers with adequate baseline vitamin C status may respond differently from people with low status. A single-dose crossover study answers a different question from a longer repeated-dose trial.

Next, check whether the study measured plasma vitamin C only or also looked at cells, urine or biological outcomes. Carr's review explicitly called for more work on urinary elimination, cellular uptake and biological effects. That knowledge gap should stay visible in marketing and technical communication.

Then check whether the tested formulation is the same as the commercial ingredient. Changes in lipid composition, drying process or active-to-carrier ratio can weaken the relevance of older data. If a supplier has modified the formulation, ask what comparability data supports carrying the evidence forward.

Our second clear position is that "clinically studied" is too broad a phrase for procurement. The useful question is whether the commercial material, at the proposed use level, is represented by the study.

Where LipoDuo™ Vitamin C fits in a responsible formulation story

Samarth Biorigins positions LipoDuo as a platform that encapsulates actives in liposomes and then stabilises them by lyophilisation. For a B2B buyer, the value of that architecture should be assessed through specifications and data rather than through generic liposome claims.

A technical discussion around LipoDuo™ Vitamin C can therefore focus on powder handling, composition, characterisation, stability, dispersion and evidence that belongs to the commercial material. That is a stronger route than promising that every consumer will absorb a fixed multiple of ordinary vitamin C.

The most defensible story is specific: liposomal vitamin C has a growing human pharmacokinetic evidence base, formulation differences are substantial, and the exact ingredient still needs to prove its quality and fit for the chosen dosage form. That is more credible than a simple superiority message, and it gives R&D teams something they can actually evaluate.

Questions the next generation of studies should answer

The 2025 evidence base leaves useful work to be done. More studies could compare commercial formulations under standardised conditions, include people with different baseline vitamin C status and collect enough samples to characterise both exposure and elimination. Cellular uptake and biologically relevant endpoints deserve more attention too.

For suppliers, that creates a research opportunity. Better evidence does not mean chasing a larger fold-change. It means linking physicochemical characterisation to pharmacokinetics, stability and the final dosage form. A clear chain from raw-material specification to human exposure is more valuable than an isolated impressive number.

There is also an honest uncertainty here: there is no single liposomal specification that guarantees clinical performance across all products. The answer depends on formulation design, dose, process and the question the study is trying to answer. Buyers should expect that uncertainty to be managed with data, not hidden by branding.

For teams evaluating LipoDuo™ Vitamin C, the sensible path is evidence plus manufacturing fit. Review the pharmacokinetic literature, then test the exact ingredient in the exact product format. That is how a delivery technology becomes a dependable formulation rather than a label claim.

The finished-product trial should mirror the real use case

A final bench trial should recreate the stress the ingredient will experience after it leaves the raw-material bag. For a sachet, that means realistic mixing time, water temperature and standing time. For a capsule, it means blend uniformity, moisture exposure and assay after filling. For a gummy or chewable, heat and water activity deserve attention because they may affect both vitamin C and the lipid system.

This application work closes the gap between pharmacokinetics and manufacturing. LipoDuo™ Vitamin C may enter development because of the liposomal rationale, but the finished product still has to prove that the ingredient remains chemically and physically suitable after processing.